Blood samples were obtained in the ranibizumab-treated eyes prior to injection and after 1, 7, 14, and 28 days. Measurement of serum VEGF by enzyme-linked immunoabsorbent assay showed a statistically significant reduction from baseline on the first day after injection, but not at any of the subsequent timepoints.
During the discussion, members of the session panel raised the question of whether laser pretreatment may alter the blood-brain barrier and affect the ability of the anti-VEGF agent to enter the bloodstream. Dr. Kusaka responded that a thorough analysis of differences in serum VEGF concentrations with patients categorized by therapeutic indication had not yet been conducted.
Dr. Kusaka has no relevant financial disclosures.